Drug profile · INN
sorafenib tosylate
NEXAVAR
sorafenib tosylate (NEXAVAR) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — sorafenib tosylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
sorafenib tosylate (NEXAVAR) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Platelet-derived growth factor receptor beta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sorafenib tosylate?
sorafenib tosylate (NEXAVAR) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sorafenib tosylate?
NEXAVAR is a marketed brand name for sorafenib tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sorafenib tosylate?
sorafenib tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.